Phase IIB randomized study of topical difluoromethylornithine and topical diclofenac on sun-damaged skin of the forearm

Cancer Prevention Research

Volumn 9, Issue 2, 2016, Pages 128-134

  Jeter, Joanne M ^a,c   Curiel Lewandrowski, Clara ^a   Stratton, Steven P ^a   Myrdal, Paul B ^b   Warneke, James A ^a   Einspahr, Janine G ^a   Bartels, Hubert G ^a   Yozwiak, Michael ^a   Bermudez, Yira ^a   Hu, Chengcheng ^b   Bartels, Peter ^b   Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DICLOFENAC; EFLORNITHINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ADVERSE EFFECTS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; FEMALE; FOLLOW UP; FOREARM; HUMAN; KERATOSIS, ACTINIC; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; SKIN; SKIN NEOPLASMS; SUNLIGHT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; DICLOFENAC; EFLORNITHINE; FEMALE; FOLLOW-UP STUDIES; FOREARM; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; PROGNOSIS; SKIN; SKIN NEOPLASMS; SUNLIGHT;

EID: 84957958604     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0232     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015.
2. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-Analysis. Arch Dermatol 2000;136: 1524-30.
3. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92.
4. Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, et al. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 2010;139:797-805.
5. Alberts DS, Dorr RT, Einspahr JG, Aickin M, Saboda K, Xu MJ, et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000;9:1281-6.
6. Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res 2010;3:35-47.
7. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723-9.
8. Asgari M, White E, Chren MM. Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol Surg 2004;30:1335-42.
9. Pirard D, Vereecken P, Melot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-Analysis of the recent studies. Arch Dermatol Res 2005;297:185-9.
10. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, openlabel assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004;3: 401-7.
11. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003;44:40-3.
12. Peterson SR, Goldberg LH. New and emerging treatments for nonmelanomas and actinic keratoses. J Drugs Dermatol 2003;2:429-32.
13. Meyskens FL Jr., McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, doubleblind trial. Cancer Prev Res 2008;1:32-8.
14. Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, Alberts DS. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res 2002;8:149-55.
15. Bozzo P, Saboda K, Einspahr JG, Ranger-Moore J, Farmer ER, Cockerell CJ, et al. Reliability and validity of a histologic score as a marker for skin cancer chemoprevention studies. Anal Quant Cytol Histol 2003;25: 285-92.
16. Irinopoulou T, Rigaut JP, Benson MC. Toward objective prognostic grading of prostatic carcinoma using image analysis. AnalQuant CytolHistol 1993; 15:341-4.
17. Susnik B, Worth A, LeRiche J, Palcic B. Malignancy-Associated changes in the breast. Changes in chromatin distribution in epithelial cells in normalappearing tissue adjacent to carcinoma. Anal Quant Cytol Histol 1995; 17:62-8.
18. Hastie TJ, Botha JL, Schnitzler CM. Regression with an ordered categorical response. Stat Med 1989;8:785-94.
19. Krouse RS, Alberts DS, Prasad AR, Yozwiak M, Bartels HG, Liu Y, et al. Progression of skin lesions from normal skin to squamous cell carcinoma. Anal Quant Cytol Histol 2009;31:17-25.